Vision RT Ltd.

Vision RT Ltd. is a technology company specializing in Surface Guided Radiation Therapy (SGRT) systems, focusing on enhancing safety and precision in cancer treatment through innovative solutions. Vision RT Ltd. was founded in 2001 and is headquartered in London, UK.

The company focuses on developing advanced SGRT solutions for oncology. In May 2018, Vision RT secured a funding round led by London Fund Managers, raising GBP 0. 250 mn, marking a notable investment in its growth strategy. The company has completed 2 deals to date and has a current valuation of GBP 9.

712 mn. The CEO, Norman Smith, has a history of leadership in the technology sector, steering Vision RT towards a focus on delivering high-precision radiotherapy solutions. Vision RT specializes in Surface Guided Radiation Therapy (SGRT) solutions, offering a suite of innovative products designed to enhance the safety, accuracy, and efficiency of radiotherapy workflows. Their core product lineup includes SimRT™, a single-camera solution for patient positioning during 4D and breath-hold CT; MapRT®, a dual-camera system for treatment planning by mapping safe beam angles; AlignRT®, a leading motion management system utilized during treatment; and DoseRT™, which visualizes radiation and detects dose delivery errors in real-time.

Vision RT has over 2,600 systems actively in clinical use across 24 of the top 25 cancer hospitals in the United States, serving a wide array of healthcare providers involved in treating various cancer types worldwide. In 2022, Vision RT reported a revenue of GBP 97. 999768 mn. The revenue model is primarily based on direct sales of SGRT systems and related software to oncology clinics and healthcare institutions.

This model is supported by long-term contracts with hospitals and cancer treatment centers, ensuring ongoing support and integration of their technologies. Their flagship products, such as AlignRT® and DoseRT™, contribute significantly to their revenue through both direct sales and potential software subscription models. Vision RT plans to enhance its product offerings and expand into new markets. They are developing new SGRT products aimed at improving treatment efficacy and patient safety, with specific timelines for launch yet to be confirmed.

The company is targeting expansion in the North American and European markets to increase its footprint in oncology. The recent funding round will support these initiatives by providing capital for research and development as well as marketing efforts to penetrate these new regions.